Advertisement

Cambridge-based Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY) said that key claims in a patent that covers molecules that mediate its RNA interference technology have been upheld in a challenge by a Japanese company.

Advertisement
Advertisement